Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and small molecule therapies for ophthalmic disorders, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.

CEO George Magrath, MD, and Chief Scientific and Development Officer Ash Jayagopal, Ph.D., MBA, will deliver a corporate update presentation, available on demand starting September 8, 2025 at 7:00 a.m. ET. The company also noted that replays from recent investor events, including a Nasdaq Spotlight interview and other presentations, are available on their website's Investors section.

News Market Reaction

+4.07%

1 alert

+4.07% News Effect

+$3M Valuation Impact

$80M Market Cap

0.1x Rel. Volume

On the day this news was published, IRD gained 4.07%, reflecting a moderate positive market reaction. This price movement added approximately $3M to the company's valuation, bringing the market cap to $80M at that time.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jayagopal, Ph.D., MBA, Chief Scientific and Development Officer, will deliver a corporate update at the H.C. Wainwright 27^th Annual Global Investment Conference being held September 8-10, 2025. The presentation will be available on demand on Monday, September 8, 2025 at 7:00 a.m. ET.

In addition, replays from other recent investor events are available on the Opus Genetics’ website, including:

• Nasdaq Spotlight interview
• Chardan Virtual Ophthalmology Summit Series on Rare Ophthalmic Diseases Fireside Chat
• Jones Trading Virtual Presbyopia Expert Panel
  

Links to these webcasts may be accessed on the Opus Genetics website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

When is Opus Genetics (IRD) presenting at the H.C. Wainwright Conference 2025?

Opus Genetics' presentation will be available on demand starting Monday, September 8, 2025 at 7:00 a.m. ET.

Who will be presenting for Opus Genetics at the H.C. Wainwright Conference?

George Magrath, MD (CEO) and Ash Jayagopal, Ph.D., MBA (Chief Scientific and Development Officer) will deliver the corporate update.

What type of treatments is Opus Genetics (IRD) developing?

Opus Genetics is developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders.

Where can investors access Opus Genetics' conference presentation and other recent webcasts?

The presentations can be accessed in the Investors section under Events on the Opus Genetics website.